Skip to main content
Micro-Tech (Nanjing) Co.,Ltd logo

Micro-Tech (Nanjing) Co.,Ltd — Investor Relations & Filings

Ticker · 688029 ISIN · CNE100003MG1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 662 across all filing types
Latest filing 2020-03-30 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688029

About Micro-Tech (Nanjing) Co.,Ltd

https://www.micro-tech.com.cn/

Micro-Tech (Nanjing) Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical devices. The company focuses on providing advanced solutions for gastroenterology, respiratory medicine, and orthopedics. Its product portfolio includes a wide range of endoscopic diagnostic and therapeutic tools such as biopsy forceps, disposable hemoclips, biliary and esophageal stents, and specialized instruments for Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD). Micro-Tech emphasizes innovation and quality, maintaining international certifications to serve a global healthcare market. By integrating precision engineering with clinical needs, the company aims to improve patient outcomes and procedural efficiency for medical professionals worldwide.

Recent filings

Filing Released Lang Actions
关于使用部分超募资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the use of a portion of over-raised funds (超募资金) to permanently supplement working capital. It includes details about the board and supervisory meetings, independent director opinions, and sponsor institution verification. The document is a formal disclosure about a financing-related decision, specifically about the use of raised capital, but it does not contain financial statements or comprehensive financial data. It is not an annual or interim report, audit report, or earnings release. It is not a call transcript or management report. The document is a regulatory announcement about capital usage, fitting the category of Capital/Financing Update (CAP). The document length is about 3,000 characters, which is typical for an announcement rather than a full report. Therefore, the best classification is CAP with high confidence.
2020-03-30 Chinese
南京证券股份有限公司关于南微医学科技股份有限公司调整部分募集资金投资建设项目内部投资结构和投资总额之核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (Nanjing Securities) regarding adjustments to the internal investment structure and total investment amount of certain fundraising projects by Nanwei Medical Technology Co., Ltd. It references regulatory approvals, fundraising amounts, and compliance with listing rules. The content focuses on the use and management of raised funds, project adjustments, and includes opinions from independent directors, the supervisory board, and the sponsor institution. It is not a full annual or interim financial report, nor an earnings release or call transcript. It is not a simple announcement or certification but a formal verification report related to fundraising project adjustments. This fits the category of Audit Report / Information (AR), which includes audit reports, applied accounting principles, and regulatory compliance verifications related to fundraising and project investment. The document length (3950 characters) is sufficient for a substantive report rather than a brief announcement. Therefore, the best classification is AR with high confidence. FY 2019
2020-03-30 Chinese
第二届监事会第八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Nanwei Medical Technology Co., Ltd. It details the decisions made in the 8th meeting of the 2nd Supervisory Board, including approval of the 2019 profit distribution plan, the 2019 Supervisory Board work report, the 2019 annual report and its summary, the 2019 financial final accounts report, the 2020 budget report, and other related matters. The document repeatedly states that these items need to be submitted to the shareholders' meeting for approval. It also references that the full annual report and other detailed reports are published separately on the Shanghai Stock Exchange website. The document itself is a formal announcement of the Supervisory Board's meeting resolutions rather than the full annual report or financial statements. The length is 2787 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of Regulatory Filings (RNS) as it is a formal regulatory announcement of meeting resolutions and not the full annual report or financial statements themselves.
2020-03-30 Chinese
2019年度独立董事述职报告
Regulatory Filings
2020-03-30 Chinese
南京证券股份有限公司关于南微医学科技股份有限公司2019年度持续督导报告书
Regulatory Filings Classification · 95% confidence The document is titled as a "2019年度持续督导报告书" (2019 Annual Continuous Supervision Report) issued by 南京证券股份有限公司 as the sponsor institution for 南微医学科技股份有限公司. It references regulatory frameworks related to securities issuance and listing supervision, specifically mentioning the Shanghai Stock Exchange's Sci-Tech Innovation Board (科创板) rules and continuous supervision guidelines. The content includes detailed descriptions of the sponsor's continuous supervision activities, risk factors, financial data analysis, compliance with fundraising usage, and shareholding information of directors and senior management. The document is a formal report on the continuous supervision work performed by the sponsor institution after the company's listing, which is a regulatory requirement in the Chinese capital markets for listed companies on the Sci-Tech Innovation Board. This type of document is not an annual report (10-K), audit report (AR), or earnings release (ER), nor is it a simple announcement or certification. It is a specialized regulatory report related to ongoing sponsor supervision. Given the nature and content, this document best fits the category of Regulatory Filings (RNS) as it is a regulatory compliance report that does not fall under other specific categories like Annual Report or Audit Report. The document length (over 10,000 characters) and detailed content confirm it is the report itself, not just an announcement. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2020-03-30 Chinese
关于2019年年度利润分配方案公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2019 annual profit distribution plan of the company 南微医学科技股份有限公司. It details the dividend per share, total dividend amount, and the decision-making process including board and supervisory opinions. It explicitly states that the profit distribution plan will be submitted to the annual shareholders meeting for approval. The document does not contain full financial statements or comprehensive financial performance data, but rather focuses on the dividend distribution plan and related corporate governance procedures. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders. The document length is short (1619 characters), and it is not a full annual report or earnings release. Therefore, the correct classification is DIV with high confidence.
2020-03-30 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.